Business Insider

New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company ...
Nasdaq

Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced interim results from the VISIBLE open-label extension (OLE) study on the long-term ...
Business Wire

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating ...
Business Wire

Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNFα Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease ...

Vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures ...
Healio

Better efficacy outcomes associated with infliximab vs. vedolizumab in Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.
MedPage Today

Vedolizumab Tied to Lower Risk for Serious Infections in Ulcerative Colitis

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Vedolizumab ...
MedPage Today

Vedolizumab Edges Out Infliximab for Ulcerative Colitis in Real-World Study

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
Monthly Prescribing Reference

Investigational Subcutaneous Vedolizumab Shows Similar Efficacy to IV: Network Meta-Analysis

Based on the network meta-analysis, study authors reported similar efficacy and safety profiles for the IV and SC formulations of vedolizumab ORLANDO – An investigational subcutaneous (SC) formulation ...
The American Journal of Managed Care

Vedolizumab First Shows Clinical and Economic Advantage in Ulcerative Colitis

Vedolizumab as a first-line biologic in UC offers cost savings and clinical benefits, improving QALYs compared to TNF-α inhibitors. In CD, vedolizumab provides incremental benefits but incurs higher ...
Medscape

Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study

When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab ...
Business Insider

New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease

OSAKA, Japan, May 8, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the effectiveness and ...